Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 7Genitourinary 3Head & Neck 2Thoracic 1NET 1Endocrine 1Dermatologic 1

Conditions

Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1

Interventions

Sunitinib 3telotristat ethyl 1romidepsin 1lutetium Lu 177 dotatate 1gallium Ga 68 dotatate 1folfirinox 1fludarabine phosphate 1fludarabine 1entrectinib 1copper dotatate CU-64 1alectinib 1Temozolomide 1TH 302 1Quality of Life 1Poly(ADP-ribose) Polymerase Inhibitors 1Plastic Surgery Procedures 1Patient Reported Outcome Measures 1Needles 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Lutetium-177 1Lutetium 1Lactones 1Immunotherapy 1Granulocyte Colony-Stimulating Factor 1Fluorodeoxyglucose F18 1Filgrastim 1FAPI-46 1Everolimus 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × TH 302 × NET × Clear all
NCT02402062 2020-07-27

A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
17 enrolled 55 charts
EndocrineGastrointestinalNET

Pancreatic Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡